Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5768)	2/27/2002 10:52:21 PM
From: Zeev Hed	Read Replies (1) \| Respond to of 52153

I must have missed something, did Enbrel get full clearance for P and PA treatment? Zeev

To: scaram(o)uche who wrote (5768)	2/28/2002 1:29:03 AM
From: software salesperson	Read Replies (1) \| Respond to of 52153

1. while it is certainly possible that one of the new biologics will be found to be efficacious against PA, i don't recall seeing any info from either bgen or dna/xoma along those lines. my focus was 2006 since most of the analysts use that timeframe in their forecasts. remicade with mtx will not amount to much competition. thus, i believe that enbrel will maintain a stranglehold over the biologic competition for PA through 2006. another point to bear in mind is that alice gottlieb is a thought-leader in the P community. so when she prescribes enbrel for P, her colleagues will listen. 2. the $ 2-3 B estimate was for US alone. 3. i have not seen any info on the non-US patient population. your estimate of 1 M seems reasonable. 4. one conclusion that can be drawn from my analysis is that any company which is counting on their product(except enbrel) to become a $ 500 M drug by 2006 in order to satisfy their business plan objectives is in for a rather rude awakening. sales